| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA5238906 | F | Antiviral activity against wild type HIV-1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral growth measured after 4 to 5 days by Dual luciferase reporter assay | Human immunodeficiency virus 1 | 28 | ALA5236606 | organism-based format | Scientific Literature | |
| 2. | ALA5238907 | F | Antiviral activity against wild type HIV-1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral growth measured after 4 to 5 days in presence of 10% FBS and 40% human serum supplemented with 27 mg/mL of human serum albumin by Dual luciferase reporter assay | Human immunodeficiency virus 1 | 25 | ALA5236606 | organism-based format | Scientific Literature | |
| 3. | ALA5238909 | F | Antiviral activity against wild type HIV-1 NLRepRlucP373S harboring deltaV370 mutant infected in human MT2 cells assessed as inhibition of viral growth measured after 4 to 5 days by Dual luciferase reporter assay | Human immunodeficiency virus 1 | 8 | ALA5236606 | organism-based format | Scientific Literature | |
| 4. | ALA5238910 | F | Antiviral activity against wild type HIV-1 NLRepRlucP373S harboring T332S/V362I/prR41G mutant infected in human MT2 cells assessed as inhibition of viral growth measured after 4 to 5 days by Dual luciferase reporter assay | Human immunodeficiency virus 1 | 24 | ALA5236606 | organism-based format | Scientific Literature | |
| 5. | ALA5238911 | F | Antiviral activity against wild type HIV-1 NLRepRlucP373S harboring V362I/V370A mutant infected in human MT2 cells assessed as inhibition of viral growth measured after 4 to 5 days by Dual luciferase reporter assay | Human immunodeficiency virus 1 | 5 | ALA5236606 | organism-based format | Scientific Literature | |
| 6. | ALA5238913 | F | Fold resistance, ratio of EC50 for antiviral activity against wild type HIV-1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral growth in presence of 10% FBS and 40% human serum supplemented with 27mg/mL of human serum albumin to EC50 for antiviral activity against wild type HIV-1 NLRepRlucP373S infected in human MT2 cells assessed as inhibition of viral growth | Human immunodeficiency virus 1 | 25 | ALA5236606 | cell-based format | Scientific Literature | |
| 7. | ALA5238914 | T | Cytotoxicity against human MT2 cells assessed as reduction in cell viability | Homo sapiens | 25 | ALA5236606 | cell-based format | Scientific Literature | |
| 8. | ALA5238915 | F | Antiviral activity against wild type HIV-1 NLRepRlucP373S harboring A326T/V362I/V370A mutant infected in human MT2 cells assessed as inhibition of viral growth measured after 4 to 5 days by Dual luciferase reporter assay | Human immunodeficiency virus 1 | 4 | ALA5236606 | organism-based format | Scientific Literature | |
| 9. | ALA5238916 | F | Antiviral activity against wild type HIV-1 NLRepRlucP373S harboring R361K/V362I/L363M mutant infected in human MT2 cells assessed as inhibition of viral growth measured after 4 to 5 days by Dual luciferase reporter assay | Human immunodeficiency virus 1 | 4 | ALA5236606 | organism-based format | Scientific Literature | |
| 10. | ALA5238917 | A | Metabolic stability in human liver microsomes assessed as half life at 0.5 uM in presence of NADPH by LC-MS/MS analysis | Homo sapiens | 4 | ALA5236606 | microsome format | Scientific Literature | |
| 11. | ALA5238918 | A | Metabolic stability in rat liver microsomes assessed as half life at 0.5 uM in presence of NADPH by LC-MS/MS analysis | Rattus norvegicus | 4 | ALA5236606 | microsome format | Scientific Literature | |
| 12. | ALA5238919 | A | Metabolic stability in dog liver microsomes assessed as half life at 0.5 uM in presence of NADPH by LC-MS/MS analysis | Canis lupus familiaris | 4 | ALA5236606 | microsome format | Scientific Literature | |
| 13. | ALA5238920 | A | Protein binding in human serum albumin assessed as fraction bound at 53 nM incubated for 1 hrs by ultracentrifugation method | Homo sapiens | 4 | ALA5236606 | cell-free format | Scientific Literature | |
| 14. | ALA5238921 | A | Solubility of compound in FaSSIF at pH 6.5 | 4 | ALA5236606 | assay format | Scientific Literature | ||
| 15. | ALA5238922 | A | Solubility of the compound in FeSSIF at pH 5.0 | 4 | ALA5236606 | assay format | Scientific Literature | ||
| 16. | ALA5238923 | A | Clearance in Sprague-Dawley rat at 1 mg/kg, iv by LC-MS/MS analysis | Rattus norvegicus | 4 | ALA5236606 | organism-based format | Scientific Literature | |
| 17. | ALA5238924 | A | Volume of distribution at steady state in Sprague-Dawley rat at 1 mg/kg, iv by LC-MS/MS analysis | Rattus norvegicus | 4 | ALA5236606 | organism-based format | Scientific Literature | |
| 18. | ALA5238925 | A | Half life in Sprague-Dawley rat at 1 mg/kg, iv by LC-MS/MS analysis | Rattus norvegicus | 4 | ALA5236606 | organism-based format | Scientific Literature | |
| 19. | ALA5238926 | A | MRT in Sprague-Dawley rat at 1 mg/kg, iv by LC-MS/MS analysis | Rattus norvegicus | 4 | ALA5236606 | organism-based format | Scientific Literature | |
| 20. | ALA5238927 | A | AUCt in Sprague-Dawley rat at 5 mg/kg, po by LC-MS/MS analysis | Rattus norvegicus | 4 | ALA5236606 | organism-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!